Drug Database · Clinicians

Ifosfamide

Brands (14) Fosfa, Ifocare, Ifosfaxil…Show all

US brand (reference label): IFEX; not a Philippine-registered brand.

Alkylating Drug (Alkylating Activity) US FDA class
Antineoplastic (nitrogen mustard analogue); Antineoplastic (alkylating agent); and others PH FDA category

Rx · Prescription drug18 PH productsPNF-listedVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID b7241707-7538-4d1a-91e7-3a25a91e0b9a, version date October 7, 2026 (IFEX · Baxter Healthcare Corporation). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • IFEX is indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE IFEX is indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer. IFEX is an alkylating drug indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer.

Contraindications

4 CONTRAINDICATIONS IFEX is contraindicated in patients with: • Known hypersensitivity to administration of ifosfamide. • Urinary outflow obstruction. • Known hypersensitivity to administration of ifosfamide. (4) • Urinary outflow obstruction. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • • Administer IFEX with extensive hydration consisting of at least 2 liters of oral or intravenous fluid per day to reduce the incidence or severity of bladder toxicity. (2.1, 5.3)
  • • Administer mesna with IFEX to reduce the incidence or severity of hemorrhagic cystitis. (2.1, 5.3)
  • • Administer IFEX as a slow intravenous infusion (at least 30 minutes) at a dose of 1.2 grams per m 2 per day for 5 consecutive days. Repeat every 3 weeks or after recovery from hematologic toxicity. (2.2)
  • • Individualize the dose and dosing schedule of IFEX based on patient risk factors and adverse reactions. (2.2)
  • • See Full Prescribing Information for instructions on preparation and administration. (2.3)
2.1 Important Administration Instructions

2.1 Important Administration Instructions Administer IFEX with extensive hydration consisting of at least 2 liters of oral or intravenous fluid per day to reduce the incidence or severity of bladder toxicity. Administer IFEX with mesna to reduce the incidence or severity of hemorrhagic cystitis [see Warnings and Precautions (5.3)].

2.2 Recommended Dosage

2.2 Recommended Dosage The recommended dosage of IFEX is 1.2 grams per m 2 per day administered as a slow intravenous infusion (lasting at least 30 minutes) for 5 consecutive days. Treatment is repeated every 3 weeks or after recovery from hematologic toxicity. Individualize the dose and dosing schedule of IFEX based on patient risk factors and adverse reactions.

2.3 Preparation and Administration

2.3 Preparation and Administration IFEX is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Skin reactions associated with accidental exposure to IFEX may occur. To minimize the risk of dermal exposure, always wear impervious gloves when handling vials and solutions containing IFEX. If IFEX solution contacts the skin or mucosa, immediately wash the skin thoroughly with soap and water or rinse the mucosa with copious amounts of water.

Prepare IFEX for intravenous use by adding Sterile Water for Injection, USP or Bacteriostatic Water for Injection, USP (benzyl alcohol or parabens preserved) to the vial and shaking to dissolve. Before administration, the substance must be completely dissolved. Use the quantity of diluents shown in Table 1 below to reconstitute the product: Table 1: IFEX Quantities for Dilution and Final Concentrations Dosage Strength Quantity of Diluent Final Concentration 1 gram 20 mL 50 mg per mL 3 grams 60 mL 50 mg per mL Solutions of ifosfamide may be diluted further to achieve concentrations of 0.6 to 20 mg/mL in the following fluids:

  • 5% Dextrose Injection, USP
  • 0.9% Sodium Chloride Injection, USP
  • Lactated Ringer’s Injections, USP
  • Sterile Water for Injection, USP Because essentially identical stability results were obtained for Sterile Water admixtures as for the other admixtures (5% Dextrose Injection, 0.9% Sodium Chloride Injection, and Lactated Ringer’s Injection), the use of large volume parenteral glass bottles, VIAFLEX bags or PAB bags that contain intermediate concentrations or mixtures of excipients (e.g., 2.5% Dextrose Injection, 0.45% Sodium Chloride Injection, or 5% Dextrose and 0.9% Sodium Chloride Injection) is also acceptable. Refrigerate constituted or constituted and further diluted solutions of IFEX and use within 24 hours. Benzyl-alcohol-containing solutions can reduce the stability of ifosfamide. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness have not been established in pediatric patients. Renal rickets and growth retardation in pediatric patients treated with ifosfamide have been reported. IFEX may cause temporary or permanent infertility in prepubertal girls or in females of child-bearing potential and may have an increased risk of developing premature menopause.

IFEX may cause abnormal secondary sexual characteristic development in prepubertal males. Sterility, azoospermia, and testicular atrophy have been reported in male patients. Azoospermia may be reversible in some patients, but may not occur for several years after cessation of IFEX therapy.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Clinical studies of IFEX did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger subjects. A study of patients 40 to 71 years of age indicated that elimination half-life appears to increase with advancing age [see Pharmacokinetics (12.3)].

This apparent increase in half-life appeared to be related to increases in volume of distribution of ifosfamide with age. No significant changes in total plasma clearance or renal or non-renal clearance with age were reported. Ifosfamide and its metabolites are known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.

Because elderly patients are more likely to have decreased renal function, closely monitor for adverse reactions and monitor renal function as clinically indicated.

Administration

2.1 Important Administration Instructions Administer IFEX with extensive hydration consisting of at least 2 liters of oral or intravenous fluid per day to reduce the incidence or severity of bladder toxicity. Administer IFEX with mesna to reduce the incidence or severity of hemorrhagic cystitis [see Warnings and Precautions (5.3) ] .

2.3 Preparation and Administration IFEX is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Skin reactions associated with accidental exposure to IFEX may occur. To minimize the risk of dermal exposure, always wear impervious gloves when handling vials and solutions containing IFEX. If IFEX solution contacts the skin or mucosa, immediately wash the skin thoroughly with soap and water or rinse the mucosa with copious amounts of water. Prepare IFEX for intravenous use by adding Sterile Water for Injection, USP or Bacteriostatic Water for Injection, USP (benzyl alcohol or parabens preserved) to the vial and shaking to dissolve. Before administration, the substance must be completely dissolved. Use the quantity of diluents shown in Table 1 below to reconstitute the product: Table 1: IFEX Quantities for Dilution and Final Concentrations Dosage Strength Quantity of Diluent Final Concentration 1 gram 20 mL 50 mg per mL 3 grams 60 mL 50 mg per mL Solutions of ifosfamide may be diluted further to achieve concentrations of 0.6 to 20 mg/mL in the following fluids: • 5% Dextrose Injection, USP • 0.9% Sodium Chloride Injection, USP • Lactated Ringer’s Injections, USP • Sterile Water for Injection, USP Because essentially identical stability results were obtained for Sterile Water admixtures as for the other admixtures (5% Dextrose Injection, 0.9% Sodium Chloride Injection, and Lactated Ringer’s Injection), the use of large volume parenteral glass bottles, VIAFLEX bags or PAB bags that contain intermediate concentrations or mixtures of excipients (e.g., 2.5% Dextrose Injection, 0.45% Sodium Chloride Injection, or 5% Dextrose and 0.9% Sodium Chloride Injection) is also acceptable. Refrigerate constituted or constituted and further diluted solutions of IFEX and use within 24 hours. Benzyl-alcohol-containing solutions can reduce the stability of ifosfamide. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

US FDA label

Dosage forms

Philippines

  • Powder for injection: 1 g, 2 g
  • Lyophilized powder for injection: 1 g, 2 g
  • Powder for solution injection: 2 g
  • Solution for infusion: 40 mg/mL
  • Solution for iv infusion: 40 mg/mL

Registered products in the Philippines

18 products registered with the Food and Drug Administration (FDA) Philippines list Ifosfamide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products18
Philippine FDA-registered products for Ifosfamide
Package insert
AmbimideIfosfamide
2 g Powder for Injection (I.V.)USP Type I flint clear glass vial (Box of 1’s)
RxVAT-exempt
Getwell Pharma India Pvt. Ltd.India
Central West Medicale Inc.Importer: Ambica International Corporation
DRP-6530-04
May 19, 2037
Cerfamide 2000Ifosfamide
2 g Lyophilized Powder For Injection (IV)50 mL- capacity Type I Clear Amber Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with Green Flip-off Cap x 1's (Box of 1's)
RxVAT-exempt
Cosmas Research Lab LimitedIndia
Medinova Pharmaceutical Inc.
DRP-18332
Jun 15, 2032
FosfaIfosfamide
1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1’s)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Genace Pharma DistributorImporter: Ambica International Corporation
DRP-6009
Feb 17, 2030
FosfaIfosfamide
2g Powder for Injection (I.V.)USP Type I flint clear glass vial (Box of 1’s)
RxVAT-exempt
Getwell Pharma India Pvt. Ltd.India
Genace Pharma DistributorImporter: Ambica International Corporation
DRP-6530
Feb 15, 2037
FosfalexIfosfamide
1 g Lyophilized Powder for Concentrate for Solution for IV InfusionUSP Type I Amber Vial with Bromobutyl Rubber Stopper and Aluminum Seal with White Flip Off Cap (Box of 1's)
RxVAT-exempt
Laboratorio Kemex S.A.Argentina
Delex Pharma International, Inc.
DRP-14002
Jun 6, 2028
Fosfasaph-2000Ifosfamide
2 g Powder For Solution Injection (I.V.)60 mL-capacity USP Type I clear glass vial with rubber stopper and aluminum light blue flip-off seal (Box of 1's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, Inc.
DRP-18710
Aug 26, 2031
FosnovaIfosfamide
1g Lyophilized Powder for Injection (IV)50mL-Capacity Type I Clear Molded Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with Blue Flip-off Cap x 1's (Box of 1's)
RxVAT-exempt
Kwality Pharmaceuticals LimitedIndia
Medinova Pharmaceutical Inc.
DRP-17903
Apr 6, 2032
Ifo-CellIfosfamide
40mg/mL Solution for IV InfusionGlass Vial x 25mL (Box of 1's)
RxVAT-exempt
Thymoorgan Pharmazie GmbHGermany
Importer: STADA Philippines Inc.
DRP-5543
May 23, 2027
IfocareIfosfamide
1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1's)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Pharma 518, Inc.Importer: Ambica International Corporation
DRP-6009-02
Feb 17, 2030
IfocareIfosfamide
2g Powder for Injection (I.V.)USP Type I flint clear glass vial (Box of 1’s)
RxVAT-exempt
Getwell Pharma India Pvt. Ltd.India
Pharma 518, Inc.Importer: Ambica International Corporation
DRP-6530-02
May 25, 2037
IfosIfosfamide
40mg/mL Solution for InfusionGlass Vial x 25mL Box of 1's
RxVAT-exempt
Thymoorgan Pharmazie GmbHGermany
Globo Asiatico Enterprises Inc.Importer: STADA Philippines Inc.Trader: STADAPHARM GmbH
DRP-5543-01
May 23, 2027
IfosfagetIfosfamide
1 g Powder for Injection (IV)USP Type I Clear Glass Vial Box of 1's
RxVAT-exempt
Getwell PharmaceuticalsIndia
2MG IncorporatedImporter: Ambica International Corporation
DRP-6009-04
Feb 17, 2030
IfosfaxilIfosfamide
1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1's)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Globo Asiatico Enterprices, Inc.Importer: Ambica International Corporation
DRP-6009-03
Feb 17, 2030
IfosfaxilIfosfamide
2 g Powder for Injection (I.V.)USP Type I flint clear glass vial (Box of 1’s)
RxVAT-exempt
Getwell Pharma India Pvt. Ltd.India
Globo Asiatico Enterprises, Inc.Importer: Ambica International Corporation
DRP-6530-03
May 19, 2037
Ifosmide-1000Ifosfamide
1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1's)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Qualimed Pharma Inc.Importer: Ambica International Corporation
DRP-6009-01
Feb 17, 2030
Ifosmide-2000Ifosfamide
2 g Powder for Injection (I.V.)USP Type I Flint Clear Glass Vial (Box of 1’s)
RxVAT-exempt
Getwell Pharma India Pvt. Ltd.India
Qualimed Pharma Inc.Importer: Ambica International Corporation
DRP-6530-01
May 20, 2037
LealfosfaIfosfamide
1 g Powder for Injection (IV)USP Type I Clear Glass Vial (Box of 1’s)
RxVAT-exempt
Getwell Pharma India Pvt. Ltd.India
Lealmeds Pharmaceutical Inc.Importer: Ambica International Corporation
DRP-6009-05
Feb 17, 2030
LealfosfaIfosfamide
2 g Powder for Injection (I.V.)USP Type I flint clear glass vial (Box of 1’s)
RxVAT-exempt
Getwell Pharma India Pvt. Ltd.India
Lealmeds Pharmaceutical Inc.Importer: Ambica International Corporation
DRP-6530-05
Feb 15, 2037

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS For injection: white, crystalline powder available in: • 1 gram single-dose vial for reconstitution • 3 gram single-dose vial for reconstitution • For injection: Single dose vials: 1 gram, 3 grams (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • • Myelosuppression: Monitor blood counts prior to treatment, during treatment, and as clinically indicated. (5.1)
  • • Encephalopathy: Monitor for signs and symptoms of CNS toxicity during and after IFEX treatment. Dose interruption or permanent discontinuation may be required based on individual safety and tolerability. (5.2)
  • • Nephrotoxicity and Urotoxicity: Monitor signs and symptoms. Monitor serum and urine chemistries. (2.1, 5.3)
  • • Cardiotoxicity: Arrhythmias, other ECG changes, and cardiomyopathy can occur and result in death. Cardiotoxicity is dose dependent and the risk is increased in patients with preexisting cardiac, treatment with other cardiotoxic agents, radiation, and renal impairment. (5.4)
  • • Pulmonary toxicity: Interstitial pneumonitis, pulmonary fibrosis, and pulmonary toxicity with fatal outcomes can occur. Monitor for signs and symptoms of pulmonary toxicity and treat as clinically indicated. (5.5)
  • • Secondary malignancies can occur. (5.6)
  • • Veno-occlusive Liver Disease can occur. (5.7)
  • • Embryo-Fetal Toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception. (5.8, 8.1, 8.3)
  • • Infertility: Can impair male and female reproductive function. (5.9)
  • • Anaphylactic/anaphylactoid reactions have been reported. (5.10)
5.1 Myelosuppression

5.1 Myelosuppression IFEX can cause myelosuppression that results in severe or fatal infections including sepsis or septic shock. Ifosfamide‑induced myelosuppression includes leukopenia, neutropenia, thrombocytopenia (with bleeding events), and anemia. The nadir of the leukocyte count usually occurs during the second week after administration of IFEX.

The risk of myelosuppression is dose‑dependent and increased in patients with reduced renal function, bone marrow metastases, prior radiation, and concomitant or prior therapy with other cytotoxic agents. Monitor complete blood counts, including leukocytes, neutrophils, platelets, and hemoglobin prior to each administration of IFEX, at appropriate intervals during treatment, and as clinically indicated.

Myelosuppression may require dosage delays. Avoid administration of IFEX to patients with a WBC count below 2000/µL, a platelet count below 50,000/µL, or when signs or symptoms of active infection or severe immunosuppression are present.

5.2 Encephalopathy

5.2 Encephalopathy IFEX can cause encephalopathy which may be fatal. Signs and symptoms may include confusion, somnolence, coma, hallucination, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, and seizures. Risk factors include high ifosfamide dosage, hypoalbuminemia, impaired renal function, poor performance status, bulky abdominal-pelvic disease, nephrotoxic treatments including cisplatin, CNS active drugs, or alcohol use.

Signs and symptoms may occur or recur within hours to days after administration of IFEX. Continue supportive care until complete resolution of CNS signs and symptoms. Monitor for signs and symptoms of encephalopathy during and after IFEX treatment. Dose interruption or permanent discontinuation may be required based on individual safety and tolerability.

Consider methylene blue for treatment of encephalopathy.

5.3 Nephrotoxicity and Urotoxicity

5.3 Nephrotoxicity and Urotoxicity IFEX can cause severe or fatal nephrotoxicity and urotoxicity including glomerular or tubular dysfunction, tubular necrosis, renal parenchymal necrosis, acute renal failure, chronic renal failure, and hemorrhagic cystitis (requiring blood transfusion). Tubular damage may occur up to years after cessation of IFEX treatment.

The risk of nephrotoxicity is increased in patients with renal impairment or reduced nephron reserve. Hemorrhagic cystitis is dose‑dependent and the risk is increased with past or concomitant radiation of the bladder or busulfan treatment. Evaluate glomerular and tubular kidney function before treatment with IFEX, during IFEX treatment, and as clinically indicated.

Monitor serum and urine chemistries (including phosphorus and potassium) and urinary sediment for the presence of erythrocytes or other signs of nephrotoxicity. Signs and symptoms may include a decrease in glomerular filtration rate, increased serum creatinine, proteinuria, enzymuria, cylindruria, aminoaciduria, phosphaturia, glycosuria, osteomalacia, tubular acidosis, Fanconi syndrome, and syndrome of inappropriate antidiuretic hormone secretion (SIADH).

Before starting treatment, exclude or correct any urinary tract obstructions [see Contraindications (4)]. During or immediately after administration, provide oral or intravenous fluid to force dieresis to reduce the risk of urinary tract toxicity. Administer mesna with IFEX to reduce the incidence and severity of urotoxicity [see Dosage and Administration (2.1)].

Obtain a urinalysis prior to each dose of IFEX. Avoid administration of IFEX in patients with active urinary tract infections. If microscopic hematuria (greater than 10 RBCs per high power field) is present, then withhold administration of IFEX until complete resolution. Further administration of IFEX should be given with vigorous oral or parenteral hydration.

Dosage interruption or permanent discontinuation may be required based on individual safety and tolerability.

5.4 Cardiotoxicity

5.4 Cardiotoxicity IFEX can cause severe or fatal cardiotoxicity including any of the following:

  • Supraventricular or ventricular arrhythmias, including atrial/supraventricular tachycardia, atrial fibrillation, pulseless ventricular tachycardia
  • Decreased QRS voltage and ST-segment or T-wave changes
  • Toxic cardiomyopathy leading to heart failure with congestion and hypotension
  • Pericardial effusion, fibrinous pericarditis, and epicardial fibrosis Cardiotoxic effects are dose‑dependent and the risk is increased in patients with cardiac disease, prior or concomitant treatment with other cardiotoxic agents, radiation of the cardiac region, and renal impairment.
5.5 Pulmonary Toxicity

5.5 Pulmonary Toxicity IFEX can cause severe or fatal pulmonary toxicities including interstitial pneumonitis, pulmonary fibrosis, and respiratory failure. Monitor for signs and symptoms of pulmonary toxicity and treat as clinically indicated.

5.6 Secondary Malignancies

5.6 Secondary Malignancies The incidence of secondary malignancies is increased in patients treated with IFEX-containing regimens. Cases of myelodysplastic syndrome, acute leukemias, lymphomas, thyroid cancers, and sarcomas have occurred and may develop several years after chemotherapy has been discontinued.

5.7 Veno-occlusive Liver Disease

5.7 Veno-occlusive Liver Disease Veno-occlusive liver disease has been reported with chemotherapy that included ifosfamide.

5.8 Embryo-Fetal Toxicity

5.8 Embryo-Fetal Toxicity Based on mechanism of action and human and animal data, IFEX can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1), Clinical Pharmacology (12.1) and Nonclinical Toxicology (13.1)]. Published literature and postmarketing reports of fetal growth restriction, oligohydramnios, fetal death, and neonatal anemia have been reported following exposure to ifosfamide‑containing chemotherapy regimens during pregnancy.

Fetal death occurred with or without intrauterine growth restriction and/or oligohydramnios. Neonatal complications associated with oligohydramnios included premature birth, pulmonary hypoplasia, acute renal failure, and neonatal death. Ifosfamide is genotoxic and mutagenic in male and female germ cells. Embryotoxic and teratogenic effects have been observed in mice, rats and rabbits at doses 0.05 to 0.075 times the human dose.

Advise pregnant women and females of reproductive potential of the potential risk to the fetus, and if ifosfamide is used during pregnancy, monitor amniotic fluid volume [see Use in Specific Populations (8.1)]. Verify the pregnancy status of females of reproductive potential prior to initiation of IFEX. Advise females of reproductive potential to use effective contraception during treatment with IFEX and for up to 12 months after completion of therapy.

Advise male patients with female partners of reproductive potential to use effective contraception during treatment with IFEX and for 6 months after completion of therapy [see Use in Specific Populations (8.1, 8.3)].

5.9 Infertility

5.9 Infertility Male and female reproductive function and fertility may be impaired in patients treated with IFEX. Ifosfamide interferes with oogenesis and spermatogenesis. Amenorrhea, azoospermia; and sterility in both sexes have been reported. Development of sterility appears to depend on the dose of ifosfamide, duration of therapy, and state of gonadal function at the time of treatment.

Sterility may be irreversible in some patients. Advise patients on the potential risks for infertility [see Use in Specific Populations (8. 3 and 8.4)].

5.10 Anaphylactic/Anaphylactoid Reactions and Cross-sensitivity

5.10 Anaphylactic/Anaphylactoid Reactions and Cross-sensitivity Anaphylactic/anaphylactoid reactions have been reported in association with ifosfamide. Cross-sensitivity between oxazaphosphorine cytotoxic agents has been reported.

5.11 Impairment of Wound Healing

5.11 Impairment of Wound Healing Ifosfamide may interfere with normal wound healing.

Drug interactions

Drug interactions (US label) US FDA label
  • • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (7.1)
  • • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (7.2)
7.1 Inducers of CYP3A4

7.1 Inducers of CYP3A4 CYP3A4 inducers may increase the metabolism of ifosfamide to its active alkylating metabolites. CYP3A4 inducers may increase the formation of the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Closely monitor patients taking ifosfamide with CYP3A4 inducers for toxicities and consider dose adjustment.

7.2 Inhibitors of CYP3A4

7.2 Inhibitors of CYP3A4 CYP3A4 inhibitors may decrease the metabolism of ifosfamide to its active alkylating metabolites, perhaps decreasing the effectiveness of ifosfamide treatment.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Ifosfamide is not a substrate for P-glycoprotein.

7 DRUG INTERACTIONS • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers.

( 7.1 ) • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide.

( 7.2 ) 7.1 Inducers of CYP3A4 CYP3A4 inducers may increase the metabolism of ifosfamide to its active alkylating metabolites.

CYP3A4 inducers may increase the formation of the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde.

Closely monitor patients taking ifosfamide with CYP3A4 inducers for toxicities and consider dose adjustment. 7.2 Inhibitors of CYP3A4 CYP3A4 inhibitors may decrease the metabolism of ifosfamide to its active alkylating metabolites, perhaps decreasing the effectiveness of ifosfamide treatment.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The most common (≥ 10%) adverse reactions were alopecia, nausea/vomiting, hematuria, leukopenia, anemia, CNS toxicity, infection. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare at phone: 1 866 888 2472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted from widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The adverse reactions in Table 2 below are based on 30 publications describing clinical experience with fractionated administration of ifosfamide as a single agent with a total dose of 4 to 12 g/m 2 per course.

Table 2: Adverse Reactions in Patients Treated with Single Agent IFEX Adverse Reaction Single Agent IFEX % (number of patients) Skin and Subcutaneous Tissue Disorders Alopecia 90% (540/603) Dermatitis 0.08% (1/1317) Papular rash 0.08% (1/1317) Gastrointestinal Disorders Nausea/Vomiting 47% (443/964) Diarrhea 0.7% (9/1317) Stomatitis 0.3% (4/1317) Renal and Urinary Disorders Hemorrhagic cystitis Includes dysuria and pollakiuria Hematuria - without mesna 44% (282/640) - with mesna 21% (33/155) Macrohematuria - without mesna 11% (66/594) - with mesna 5% (5/97) Renal dysfunction Includes acute renal failure, irreversible renal failure (fatal outcomes) serum creatinine increased, BUN increased, creatinine clearance decreased, metabolic acidosis, anuria, oliguria, glycosuria, hyponatremia, uremia, creatinine clearance increased -- Renal structural damage Includes acute tubular necrosis, renal parenchymal damage, enzymuria, cylindruria, proteinuria -- Blood and Lymphatic System Disorders Leukopenia Includes neutropenia, granulocytopenia, lymphopenia, and pancytopenia (any) -- Leukopenia <1 x 10 3 /µL 44% (267/614) Anemia Includes anemia and decrease in hemoglobin/hematocrit 38% (202/533) Thrombocytopenia Includes severe or fatal bleeding (any) -- Thrombocytopenia, 50 x 10 3 /µL 4.8% (35/729) Nervous System Disorders Central nervous system toxicity Includes coma and death Includes abnormal behavior, affect lability aggression, agitation, anxiety, aphasia, asthenia, ataxia, cerebellar syndrome, cerebral function deficiency, cognitive disorder, coma, confusional state, convulsions, cranial nerve dysfunction, depressed state of consciousness, depression, disorientation, dizziness, electroencephalogram abnormal, encephalopathy, flat affect, hallucinations, headache, ideation, lethargy, memory impairment, mood change, motor dysfunction, muscle spasms, myoclonus, progressive loss of brainstem reflexes, psychotic reaction, restlessness, somnolence, tremor, urinary incontinence 15% (154/1001) Peripheral neuropathy 0.4% (5/1317) Infections and Infestations Infection 10% (112/1128) General Disorders and Administration Site Conditions Phlebitis Includes phlebitis and irritation of the venous walls 2.8% (37/1317) Neutropenic fever Includes granulocytopenic fever 1% (13/1317) Fatigue 0.3% (4/1317) Malaise Unable to calculate Hepatobiliary Disorders Hepatotoxicity Includes increased serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), alkaline phosphatase, gamma-glutamyltransferase (GGT) and lactate dehydrogenase (LDH) 1.8% (22/1190) Metabolism and Nutrition Disorders Anorexia 1.1% (15/1317) Cardiac Disorders Cardiotoxicity Includes severe or fatal congestive heart failure, tachycardia, pulmonary edema 0.5% (7/1317) Vascular Disorders Hypotension Includes shock and death 0.3% (4/1317)

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of IFEX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and Lymphatic Disorders: agranulocytosis, febrile bone marrow aplasia, bone marrow failure, disseminated intravascular coagulation, hemolytic anemia, hemolytic febrile uremic syndrome, methemoglobinemia, neonatal anemia Cardiac Disorders: cardiac arrest*, cardiac failure*, arrhythmia*, cardiomyopathy*, cardiotoxicity, cardiac shock, ejection fraction decreased*, myocardial infarction*, myocarditis*, ventricular fibrillation*, ventricular tachycardia*, angina pectoris, atrial fibrillation, atrial flutter, bradycardia, bundle branch block left, bundle branch block right, congestive cardiomyopathy, electrocardiogram ST – segment abnormal, electrocardiogram QRD complex abnormal, electrocardiogram T-wave inversion, myocardial depression, myocardial hemorrhage, left ventricular failure, premature atrial contractions, palpitations, pericardial effusion, pericarditis, supraventricular extrasystoles, ventricular extrasystoles Congenital Disorders: fetal growth retardation Ear Disorders: deafness, hypoacusis, tinnitus, vertigo Endocrine Disorder: SIADH Eye Disorders: conjunctivitis, eye irritation, vision blurred, visual impairment Gastrointestinal Disorders: abdominal pain, cecitis, colitis, constipation, enterocolitis, ileus, gastrointestinal hemorrhage, mucosal ulceration, pancreatitis, salivary hypersecretion General Disorders and Administrative Site Conditions: multi‑organ failure*, chest pain, chills, injection/infusion site reactions (including erythema, inflammation, pain, pruritus, swelling, tenderness), edema, general physical deterioration, mucosal inflammation, pain, pyrexia Hepatobiliary Disorders: hepatic failure*, hepatitis fulminant* cholestasis, cytolytic hepatitis, portal vein thrombosis, veno‑occlusive liver disease Immune System Disorders: anaphylactic reaction, angioedema, hypersensitivity reaction, immunosuppression, urticaria Infections: The following manifestations have been associated with myelosuppression and immunosuppression caused by ifosfamide: increased risk for and severity of infections†, pneumonias†, sepsis and septic shock (including fatal outcomes), as well as reactivation of latent infections, including viral hepatitis†, Pneumocystis jiroveci †, herpes zoster, Strongyloides, progressive multifocal leukoencephalopathy†, and other viral and fungal infections † Severe immunosuppression has led to serious, sometimes fatal, infections Metabolic and Nutrition Disorders: hypocalcemia, hypokalemia, hypophosphatemia, hyperglycemia, metabolic acidosis, polydipsia, tumor lysis syndrome Musculoskeletal and Connective Tissue Disorders: arthralgia, growth retardation, myalgia, muscle twitching, osteomalacia, pain in extremity, rhabdomyolysis, rickets Neoplasms: secondary malignancies*, acute lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, myelodysplastic syndrome, Non‑Hodgkin’s lymphoma, renal cell carcinoma, sarcomas, thyroid cancer Nervous System Disorders: seizure*, asterixis, dysarthria, dysesthesia, extrapyramidal disorder, fecal incontinence, gait disturbance hypothesia, leukoencephalopathy, movement disorder, neuralgia, paresthesia, polyneuropathy, reversible posterior leukoencephalopathy syndrome.

Ifosfamide has been reintroduced after neurotoxicity. While some patients did not experience neurotoxicity, others had recurrent, including fatal, events. Psychiatric Disorders: amnesia, bradyphrenia, catatonia, delirium, delusion, echolalia, logorrhea, mania mental status change, mutism, paranoia, panic attack, perseveration Renal and Urinary Disorders: aminoaciduria, diabetes insipidus, enuresis, Fanconi syndrome, feeling of residual urine, nephrogenic phosphaturia, polyuria, tubulointerstitial nephritis Reproductive System and Breast Disorders: amenorrhea, azoospermia, decreased blood estrogen, impairment of spermatogenesis, increased blood gonadotrophin, infertility, oligospermia, ovarian disorder, ovarian failure, ovulation disorder, premature menopause Respiratory, Thoracic, and Mediastinal Disorders: acute respiratory distress syndrome*, pulmonary fibrosis*, pneumonitis*/interstitial lung disease*, pulmonary edema*, pulmonary hypertension*, respiratory failure*, alveolitis allergic, bronchospasm, cough, dyspnea, hypoxia, pleural effusion Skin and Subcutaneous Disorders: erythema, facial swelling, hyperhidrosis, macular rash, nail disorder, palmar‑plantar erythrodysesthesia syndrome, petechiae, pruritus, radiation recall dermatitis, rash, skin hyperpigmentation, skin necrosis, Stevens‑Johnson syndrome, toxic epidermal necrolysis Vascular Disorders: capillary leak syndrome, deep vein thrombosis, flushing, hypertension, pulmonary embolism, vasculitis * Includes fatal outcomes

Adverse reaction frequency tables (US label) US FDA label
- without mesna - with mesna - without mesna - with mesna
Table 2: Adverse Reactions in Patients Treated with Single Agent IFEX
Adverse Reaction Single Agent IFEX % (number of patients)
Skin and Subcutaneous Tissue Disorders
Alopecia 90% (540/603)
Dermatitis 0.08% (1/1317)
Papular rash 0.08% (1/1317)
Gastrointestinal Disorders
Nausea/Vomiting 47% (443/964)
Diarrhea 0.7% (9/1317)
Stomatitis 0.3% (4/1317)
Renal and Urinary Disorders
Hemorrhagic cystitisIncludes dysuria and pollakiuria
Hematuria
44% (282/640)
21% (33/155)
Macrohematuria
11% (66/594)
5% (5/97)
Renal dysfunctionIncludes acute renal failure, irreversible renal failure (fatal outcomes) serum creatinine increased, BUN increased, creatinine clearance decreased, metabolic acidosis, anuria, oliguria, glycosuria, hyponatremia, uremia, creatinine clearance increased --
Renal structural damageIncludes acute tubular necrosis, renal parenchymal damage, enzymuria, cylindruria, proteinuria --
Blood and Lymphatic System Disorders
LeukopeniaIncludes neutropenia, granulocytopenia, lymphopenia, and pancytopenia (any) --
Leukopenia <1 x 103/µL 44% (267/614)
AnemiaIncludes anemia and decrease in hemoglobin/hematocrit 38% (202/533)
ThrombocytopeniaIncludes severe or fatal bleeding (any) --
Thrombocytopenia, 50 x 103/µL 4.8% (35/729)
Nervous System Disorders
Central nervous system toxicityIncludes coma and death Includes abnormal behavior, affect lability aggression, agitation, anxiety, aphasia, asthenia, ataxia, cerebellar syndrome, cerebral function deficiency, cognitive disorder, coma, confusional state, convulsions, cranial nerve dysfunction, depressed state of consciousness, depression, disorientation, dizziness, electroencephalogram abnormal, encephalopathy, flat affect, hallucinations, headache, ideation, lethargy, memory impairment, mood change, motor dysfunction, muscle spasms, myoclonus, progressive loss of brainstem reflexes, psychotic reaction, restlessness, somnolence, tremor, urinary incontinence 15% (154/1001)
Peripheral neuropathy 0.4% (5/1317)
Infections and Infestations
Infection 10% (112/1128)
General Disorders and Administration Site Conditions
PhlebitisIncludes phlebitis and irritation of the venous walls 2.8% (37/1317)
Neutropenic feverIncludes granulocytopenic fever 1% (13/1317)
Fatigue 0.3% (4/1317)
Malaise Unable to calculate
Hepatobiliary Disorders
HepatotoxicityIncludes increased serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), alkaline phosphatase, gamma-glutamyltransferase (GGT) and lactate dehydrogenase (LDH) 1.8% (22/1190)
Metabolism and Nutrition Disorders
Anorexia 1.1% (15/1317)
Cardiac Disorders
CardiotoxicityIncludes severe or fatal congestive heart failure, tachycardia, pulmonary edema 0.5% (7/1317)
Vascular Disorders
HypotensionIncludes shock and death 0.3% (4/1317)

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on mechanism of action [see Clinical Pharmacology (12.1)], and human and animal data (see Data), IFEX can cause fetal harm when administered to a pregnant woman. Published literature and postmarketing reports of fetal growth restriction, oligohydramnios, fetal death, and neonatal anemia have been reported following exposure to ifosfamide‑containing chemotherapy regimens during pregnancy.

Fetal death occurred with or without intrauterine growth restriction and/or oligohydramnios. Neonatal complications associated with oligohydramnios included premature birth, pulmonary hypoplasia, acute renal failure, and neonatal death. Advise pregnant women of the potential risk to the fetus, and if ifosfamide is used during pregnancy, monitor amniotic fluid volume.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Animal studies indicate that ifosfamide is capable of causing gene mutations and chromosomal damage in vivo. In pregnant mice, resorptions increased and anomalies were present at day 19 after a 30 mg/m 2 dose of ifosfamide was administered on day 11 of gestation.

Embryo-lethal effects were observed in rats following the administration of 54 mg/m 2 doses of ifosfamide from the 6th through the 15th day of gestation and embryotoxic effects were apparent after dams received 18 mg/m 2 doses over the same dosing period. Ifosfamide is embryotoxic to rabbits receiving 88 mg/m 2 /day doses from the 6th through the 18th day after mating.

The number of anomalies was also significantly increased over the control group.

Mechanism of action

12.1 Mechanism of Action Ifosfamide is a prodrug that requires metabolic activation by hepatic cytochrome P450 isoenzymes to exert its cytotoxic activity. Activation occurs by hydroxylation at the ring carbon atom forming the unstable intermediate 4-hydroxyifosfamide and its ring-opened aldo tautomer, which decomposes to yield the cytotoxic and urotoxic compound acrolein and an alkylating isophosphoramide mustard.

The exact mechanism of action of ifosfamide has not been determined, but its cytotoxic action is primarily through DNA crosslinks caused by alkylation by the isophosphoramide mustard at guanine N-7 positions. The formation of inter- and intra-strand cross-links in the DNA results in cell death.

US FDA label

Pharmacokinetics

Half-life and elimination (verbatim, US label)

At single doses of 3.8 to 5.0 g/m 2 , the plasma concentrations decay biphasically and the mean terminal elimination half-life is about 15 hours.

At doses of 1.6 to 2.4 g/m 2 /day, the plasma decay is monoexponential and the terminal elimination half-life is about 7 hours.

Following intravenous administration of 1.5 g/m 2 over 0.5 hour once daily for 5 days to 15 patients with neoplastic disease, a decrease in the median elimination half-life from 7.2 hour on Day 1 to 4.6 hours on Day 5 occurred with a concomitant increase in the median clearance from 66 mL/min on Day 1 to 115 mL/min on Day 5.

Excretion After administration of doses of 5 g/m 2 of 14 C-labeled ifosfamide, from 70% to 86% of the dosed radioactivity was recovered in urine as metabolites, with about 61% of the dose excreted as parent compound.

At doses of 1.6 to 2.4 g/m 2 only 12% to 18% of the dose was excreted in the urine as unchanged drug within 72 hours.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Ifosfamide exhibits dose-dependent pharmacokinetics in humans. At single doses of 3.8 to 5.0 g/m 2, the plasma concentrations decay biphasically and the mean terminal elimination half-life is about 15 hours. At doses of 1.6 to 2.4 g/m 2 /day, the plasma decay is monoexponential and the terminal elimination half-life is about 7 hours.

Ifosfamide exhibits time-dependent pharmacokinetics in humans. Following intravenous administration of 1.5 g/m 2 over 0.5 hour once daily for 5 days to 15 patients with neoplastic disease, a decrease in the median elimination half-life from 7.2 hour on Day 1 to 4.6 hours on Day 5 occurred with a concomitant increase in the median clearance from 66 mL/min on Day 1 to 115 mL/min on Day 5.

There was no significant change in the volume of distribution on Day 5 compared with Day 1. Distribution Ifosfamide volume of distribution (Vd) approximates the total body water volume, suggesting that distribution takes place with minimal tissue binding. Following intravenous administration of 1.5 g/m 2 over 0.5 hour once daily for 5 days to 15 patients with neoplastic disease, the median Vd of ifosfamide was 0.64 L/kg on Day 1 and 0.72 L/kg on Day 5.

Ifosfamide shows little plasma protein binding. Ifosfamide and its active metabolites are extensively bound by red blood cells. Ifosfamide is not a substrate for P-glycoprotein. Metabolism Ifosfamide is extensively metabolized in humans through two metabolic pathways: ring oxidation ("activation") to form the active metabolite, 4-hydroxy-ifosfamide and side-chain oxidation to form the inactive metabolites, 3-dechloro-ethylifosfamide or 2-dechloroethylifosfamide with liberation of the toxic metabolite, chloroacetaldehyde.

Small quantities (nmol/mL) of ifosfamide mustard and 4‑hydroxyifosfamide are detectable in human plasma. Metabolism of ifosfamide is required for the generation of the biologically active species and while metabolism is extensive, it is also quite variable among patients. Excretion After administration of doses of 5 g/m 2 of 14 C-labeled ifosfamide, from 70% to 86% of the dosed radioactivity was recovered in urine as metabolites, with about 61% of the dose excreted as parent compound.

At doses of 1.6 to 2.4 g/m 2 only 12% to 18% of the dose was excreted in the urine as unchanged drug within 72 hours. Two different dechloroethylated derivatives of ifosfamide, 4-carboxyifosfamide, thiodiacetic acid and cysteine conjugates of chloroacetic acid have been identified as the major urinary metabolites of ifosfamide in humans and only small amounts of 4‑hydroxyifosfamide and acrolein are present.

Specific Populations Pediatric Patients Population PK analysis was performed on plasma data from 32 pediatric patients various malignant diseases aged between 1 and 18 years. Patients received a total of 45 courses of ifosfamide at doses of 1.2, 2.0 and 3.0 g/m 2 given intravenously over 1 or 3 hours on 1, 2, or 3 days.

The mean±standard error population estimates for the initial clearance and volume of distribution of ifosfamide were 2.4±0.33 L/h/m 2 and 21±1.6 L/m 2 with an interindividual variability of 43% and 32%, respectively. Effect of Age A study of 20 patients between 40 to 71 years of age receiving 1.5 g/m 2 of ifosfamide daily for 3 or 5 days indicated that elimination half‑life appears to increase with age.

The elimination half‑life increase appeared to be related to the increase in ifosfamide volume of distribution with age. No significant changes in total plasma clearance or renal clearance with age were reported.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Ifosfamide 1 g Vial₱948.00–₱2,000.00Reference ₱1,250.00per vialDPRI procurement range
Ifosfamide 2 g Vial₱2,100.00–₱2,750.00Reference ₱2,100.00per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Ifosfamide
PNF listingInj.: powder, 1 g and 2 g vial (IV infusion)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. IFEX · Baxter Healthcare Corporation [US FDA-approved label, version 21, October 7, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7241707-7538-4d1a-91e7-3a25a91e0b9a
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .